The research company Dextech announces that all nine included myeloma patients in a study at Karolinska Universitetssjukhuset Huddinge and Uddevalla Sjukhus responded positively to treatment with ODX, according to a press release."The patients are being followed as planned after completion of ODX treatment, in order to map when the disease progresses again. The disease-slowing effect remains in some cases even after ODX treatment has been discontinued, for at most six months," it says. The company's CEO Anders R Holmberg describes the results as remarkable. "That the disease-slowing effect remains even after completion of ODX treatment is surprising. I believe the results will arouse interest in ODX for the indication multiple myeloma, moreover with an absence of serious side effects," he says.